If you thought AbbVie CEO Richard Gonzalez spent a lot on personal air travel in 2016, check out 2017’s numbers.
Incyte CEO Hervé Hoppenot scored a big pay raise in 2017, even after the FDA rebuffed the highly anticipated RA drug it's developing with Eli Lilly.
Pfizer’s board of directors is providing rich incentives to keep CEO Ian Read on board as the company navigates a host of challenges.
Investors who pressed GSK to slash CEO Emma Walmsley’s pay package before she took the helm probably won’t much like her 2017 compensation.
Despite uncertainty heading into 2017, most drug stocks escaped the stagnation of 2016—some far more than others.
Drug spending in developed countries will fall this year, IQVIA says. The curbing effect? Rebates that more than offset pharma's price-hike haul.
Sanofi is off the hook with Justice Department in a foreign bribery investigation but is still talking with the SEC about the matter.
Daiichi Sankyo, which has struggled since losing exclusivity for its blood pressure drug Benicar, is cutting another 280 jobs in the U.S.
After Lilly CEO David Ricks took over in 2016, he revamped management while cutting costs and jobs—and earned nearly $16 million in pay for his efforts.
Mylan is suffering in the U.S. thanks to stepped-up pricing pressure. But it’s hoping a new biosimilar can eventually help its stateside sales.